Skip to main content
EnglishEN
pdf-header

Ultrasensitive BIOsensing platform for multiplex CELLular protein PHEnotyping at single-cell level

Project description

DEENESFRITPL

Groundbreaking lab-on-a-chip for cancer diagnosis

Circulating tumour cells (CTCs), carried around the body in the blood circulation, are responsible for cancer metastasis. The EU-funded BIOCELLPHE project proposes the generation of engineered bacteria that can identify and bind to specific protein targets on the surface of CTCs, triggering the production of chemical signals that can be identified with extreme sensitivity using surface-enhanced Raman scattering (SERS). SERS is an analytical technique employing plasmonic nanoparticles as optical enhancers for ultrasensitive chemical analysis at a single-molecule detection level. Researchers will create a lab-on-a-chip SERS device for the ultrasensitive identification and multiplex phenotyping of CTCs. This initiative will pave the way for a new era of medical diagnostics, providing a new paradigm for biology and biomedicine.

Objective

BIOCELLPHE provides frontier scientific and technological advancements to generate a breakthrough technology realizing the identification of proteins (i.e. phenotyping) as diagnostic biomarkers at single-cell level with unmatched sensitivity, multiplexing capabilities and portability. BIOCELLPHE proposes the generation of engineered bacteria able to recognize and bind to specific protein targets on the surface of circulating tumor cells (CTCs) responsible for cancer metastasis, thereby triggering the production of chemical signals that can be detected simultaneously, and with extremely high sensitivity by surface-enhanced Raman scattering (SERS). SERS is a powerful analytical technique that employs plasmonic nanoparticles as optical enhancers for ultrasensitive chemical analysis achieving single-molecule detection level. BIOCELLPHE will implement these advancements toward the generation of an optofluidic lab-on-a-chip SERS device enabling ultrasensitive identification and multiplex phenotyping of CTCs. We anticipate that BIOCELLPHE long-term vision and scientific breakthrough will lead to a sky limit technology that will be widely applicable, not only in the diagnostic arena, but also in many other applications (e.g. biomedical, environmental). No one has previously been able to attempt this vision due to current challenges and technical limitations, but we believe to be in a position to pave a way for achieving this now. To realize this highly ambitious project, BIOCELLPHE gathers a highly multidisciplinary community of leading experts in synthetic biology, nanotechnology, plasmonics, microfluidics, artificial intelligence, and cancer diagnosis. We believe that successful deployment of BIOCELLPHE has the potential to usher in a new era of medical diagnostics and it will provide new paradigms in biology and biomedicine, advancing frontier science and technologies at the European academic and industrial sectors.

Fields of science

Programme(s)

Topic(s)

Call for proposal

H2020-FETOPEN-2018-2020

See other projects for this call

Sub call

H2020-FETOPEN-2018-2019-2020-01

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSIDAD DE VIGO
Net EU contribution
€ 708 000,00
Address
Lg campus lagoas marcosende
36310 Vigo pontevedra
Spain

See on map
Region
Noroeste Galicia Pontevedra
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 0,00

Participants (8)

Share this page

Download

Last update: 15 September 2022
Record number: 233343

My Booklet

Permalink: /project/id/965018

European Union, 2023